Search

Your search keyword '"Syrigos, Konstantinos"' showing total 1,579 results

Search Constraints

Start Over You searched for: Author "Syrigos, Konstantinos" Remove constraint Author: "Syrigos, Konstantinos"
1,579 results on '"Syrigos, Konstantinos"'

Search Results

2. The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS

3. Knowledge and perceptions about COVID-19 among health care workers: Evidence from COVID-19 hospitals during the second pandemic wave

4. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

6. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

9. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

10. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

11. Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece

12. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

13. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

14. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

15. AI and Big Data for Drug Discovery

16. AI and Big Data for Cancer Segmentation, Detection and Prevention

17. Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece

18. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

19. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

20. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

21. Endothelial dysfunction in acute and long standing COVID−19: A prospective cohort study

24. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

25. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

26. Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial

33. Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lung and the Predictive Value of miR-375. The LANCE Trial, a Pilot Study

34. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

35. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

38. AI and Big Data for Drug Discovery

39. AI and Big Data for Cancer Segmentation, Detection and Prevention

40. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

41. Tumor-induced neoneurogenesis and perineural tumor growth: a mathematical approach

42. Chatbots in Cancer Applications, Advantages and Disadvantages: All that Glitters Is Not Gold.

43. Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.

45. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

48. Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade

50. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Catalog

Books, media, physical & digital resources